Scientists from the CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN) have discovered that the intestinal microbiota in children with type 1 diabetes is different from that of healthy children, which opens the door to the development of new therapies to control the progress of the disease by modifying the intestinal flora.
The study, published in ‘Diabetes Care’, has been led by the Biomedical Research Institute of Malaga (IBIMA) and the Endocrinology Service of the Virgen de la Victoria Hospital in Malaga. The methodology was based on the analysis of the intestinal microbiota profile, its functional capacity, inflammation and intestinal permeability in 15 children with diabetes1, another 15 children with MODY2 (a type of monogenic diabetes of non-autoimmune cause) and 13 in healthy children .
The data show that children with diabetes1 had a profile of intestinal microbiota with a lower diversity and a higher proportion of proinflammatory bacteria. In addition, it was associated with an alteration in the integrity of the intestinal barrier and with an increase in low-grade inflammation and autoimmune response compared with children with MODY and with healthy children.
